Confidential Informant Accountability Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
60pct
21d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
Confidential Informant Accountability Act of 2015 Directs the Departments of Justice, Homeland Security, and Treasury to report biannually to Congress on: (1) all serious crimes, authorized and unauthorized, committed by informants maintained by their respective law enforcement agencies (i.e., the Federal Bureau of Investigation, the Drug Enforcement Administration, the U.S. Secret Service, U.S. Immigration and Customs Enforcement, and the Bureau of Alcohol, Tobacco, Firearms and Explosives); and (2) the amounts expended by each of such agencies on payments to such informants. Defines a "serious crime" as any serious violent felony or drug offense or any offense of racketeering, bribery, child pornography, obstruction of justice, or perjury that an agent or employee of the relevant law enforcement agency has reasonable grounds to believe an informant has committed.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2015 · second_quarter · Health Issues
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Client expense: $410,000 · Firm income: Not reported
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Referred to the House Committee on the Judiciary.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Client expense: $790,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE